CA2679232C — Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
Assigned to Bayer Intellectual Property GmbH · Expires 2016-07-05 · 10y expired
What this patent protects
The present application relates to substituted 4-ary1-1,4-dihydro-1,6-naphthyridine-3-carboxamides of the formula (I): (see formula I) wherein D, Ar, R1, R2 and R3 are described herein, a process for their preparation, and their use as mineralocorticoid receptor antagonists.
USPTO Abstract
The present application relates to substituted 4-ary1-1,4-dihydro-1,6-naphthyridine-3-carboxamides of the formula (I): (see formula I) wherein D, Ar, R1, R2 and R3 are described herein, a process for their preparation, and their use as mineralocorticoid receptor antagonists.
Drugs covered by this patent
- Kerendia (FINERENONE) · Bayer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.